Ahammune Biosciences

Pune, India· Est. 2020

Ahammune Biosciences develops targeted small molecule therapies for chronic skin diseases, with a lead program for vitiligo that has completed Phase 1 trials.

ahammune.com

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

Private Company

Funding information not available

AI Company Overview

Ahammune Biosciences develops targeted small molecule therapies for chronic skin diseases, with a lead program for vitiligo that has completed Phase 1 trials.

Immunology

Technology Platform

Small molecule platform targeting deregulated cellular pathways in chronic skin diseases to restore homeostatic states, with a focus on autoimmune mechanisms.

Opportunities

Significant unmet need in vitiligo treatment market with potential for first-in-class therapy; platform technology could expand to other autoimmune skin conditions like psoriasis or alopecia areata.

Risk Factors

Clinical development risks for novel mechanism; competition from larger dermatology-focused pharmaceutical companies; regulatory challenges for first-in-class autoimmune skin therapies.

Competitive Landscape

Competes against symptomatic vitiligo treatments like topical corticosteroids and calcineurin inhibitors; potential competition from other biotechs targeting autoimmune pathways; differentiation through first-in-class mechanism and potential for permanent relief.

More companies in India →